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Merck’s Motivation
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* Source:  BioPlan 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production
• Merck lags other major biopharma companies on installed SS bioreactor capacity*
• Can this “disadvantage” be leveraged into a competitive advantage?
Facility of the Future 
CHO mAb Processing Vision at Merck
Component Engng
‘lego’ building blocks
…
Pro
duct
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Pro
duct
Bag
Pro
duct
Bag
Pro
duct
Bag
Molded parts 
Automated Continuous Processing Adaptive Process Control 
Predictive MDVA  models
Real Time Release Testing
PAT tools
SU operations
Single use Workflows
Buffer supply
Fluid flow management 
Equipment Performance 
Real time Monitoring 
Examples:
Real time sensing of Pump seal failure, 
PAT sensor performance
•Proactive preventative maintenance to 
limit failures 
•Eqpt redundancy strategy 
•Process flow strategy for deviationsAutomated Inventory 
management
A Sandbox for the Facility of Future
Protein Refinery Operations (PRO Lab)
Advanced 
Control
Operationalize
Sandbox
Facility
Facility of the 
Future
Continuous
Process
• PAT & sampling integration
• Process monitoring and MVDA modeling
• Adaptive/feedback unit operation control
• Robust control strategies
• Connections and piping
• Component engineering
• Component change-outs (filters etc.)
• Liquid and RM management
• Medium-scale operation 
• PAT & control implementation
• Batch demonstrations
• Applying facility of the future principles
• Robust manufacturing platform
PRO Lab
PRO Lab Timeline
1H 2014 2H 2014 1H 2015 2H 2015 1H 2016
Base
Protein A
Product
Viral Inactivation
Loop (In-Spec)
Acid Mixer
Out of Spec return
Quenched
Protein A Product to AEX
Define Base Control Strategies
& Order Components
Order & Install 
Components
B#1
40 Days 
Debugging
B#2
50-70 Days 
(On-Going)
MVDA Modeling
& Perturbation Analysis
$
$
PRO Lab:
Fully automated mAb drug substance
Media 
Feed
BioSMB BioSMB
• Distributed control for all unit ops
• Overview & unit-ops level views
• Batch executive tool for step 
coordination and reporting
• Unit operation flexibility
PRO Lab Layout
• Upstream area for perfusion 
bioreactor
• Downstream unit operations in 
connected “U” shape
• Routine operations at 10L 
bioreactor
• Analytical hub
• Buffer/media holds outside of 
process area
• Hardware agnostic
Analytical 
Hub
Operating Principles
A Lights-Out Approach
• Each unit operation represented
• Surge vessels used to collect and feed next unit operation
• Stream adjustments & sampling in surge vessels
• Redundant filters
• Speed compensated methods with breakpoints
• SU/closed processing methodology
Upstream
Perfusion Operations
Media 
Feed
BioSMB BioSMB
10L Glass 10L SUB 50L SUB 200L-500L SUB
• Routine operation at 10L scale
• 50L scale-up demonstrations
• SU AutoTFF cell retention device
• Weldable filter replacements
1Q 2016 3Q 2016
Baseline Perfusion Performance
• Stable cell density
• Viability maintained >99%
• Productivities > 1g/(L·Day)
• Membrane fouling and antibody 
sieving
• Significant cell lysis
Upstream Operation Performance
Cell Culture Operation
Capacitance Measurement 
• Capacitance for “in-vivo” biomass 
monitoring 
• Correlation of online and offline 
biomass measurement
• Used to automate cell bleed and 
maintain constant biomass
*Kistler, Napoli, Chen, Xu
Downstream Operations
Protein A Chromatography
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Protein A Chromatography
• Predictable reproducible elution
• Low feed pressure
• Accelerated column lifetime
Systems Closure
• Guard Filter Performance
• 1 Guard filter per day 1 guard filter 
per batch
• Volume based filter switching
PLB1
PLB1
PLB2
PLB2
Automated Sample Collection & Analysis
In-tank clarification
• Ceramic membrane sampling device
• Automated sample management
• Integration with 3rd party analytics
• Sieving of product with surface fouling
External clarification
• Sanitized sample port
• Cell removal device
• Automated sample management & 
integration with 3rd party analytics
• Hybrid solution targeted January 2016
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
m
g
/
m
L
)
Continuous Processing: 
PAT, Automated Control & Real Time Release
Media 
Feed Surge
Bag
Surge
Bag
Surge
Bag
Surge
Bag
Surge
Bag
Surge
Bag DS Fill or 
DP 
Manufacture
QbD Design Space
KPA’s & CQA’s
• End Product Testing transition to Real Time Release Testing 
• Real time automated control: process responds to variability & disturbances
• End to end prediction models for complete process
• RM control    Process input     Product quality & yield 
Process 
monitoring
Adaptive
control
Critical 
inputs  
(raw materials)
BioProcess 
Control 
RM Screening
Experience learning MVDA
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Multi Attribute Method via Peptide Mapping
LC-MS TIC
“Direct measurement of CQA’s at molecular level”
Quality Attribute Current Method
Identity Immunoassay
Glycans HILIC-Fluor
Charge Variants CEX-HPLC
Oxidation HIC
Clips rCE-SDS
Process Impurities HCP/ProA ELISA
MAM
Peptide Mapping
30 min Tryptic digest—Ren, D. et. al. Anal Biochem. 2009 Sep 1;392(1):12-21
MAM—Rogers, R. S. et. al. mAbs 2015 Sep 3;7(5):881-90
PAT UPLC Process Monitoring 
Perfusion profile monitoring
(SEC) 
Media/HCP 
components of 
interest
mAb
• SEC quality and permeate 
monitoring
• Water soluble vitamins with QDA 
MS Detector
• Multi-attribute peptide mapping 
methods installation in 1Q 2016
Continuous Process Performance
Perturbation Analysis 
Media 
Feed
SMB SMB
Upon reaching steady state, purity and 
quality attributes remain consistent
• More complex perturbation analysis 
expected with MAM method
• Predicting outcomes from indicator 
process intermediates
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Continuous Capture Duration [Days]
Low pH Excursion
Base
Protein A
Product
Viral Inactivation
Loop (In-Spec)
Acid Mixer
Out of Spec return
Quenched
Protein A Product to AEX
• A fully automated continuous bioprocessing suite has been 
established at Merck with distributed control via DeltaV
• The facility has been designed using “lights out” and closed 
processing approaches
• Two perfusion batches have been demonstrated in the lab to 
date achieving steady state cell densities for >50 days
• PRO Lab will serve as a sandbox for new sampling, PAT and MVDA 
strategies with ultimate feedback and adaptive control
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